Primary Biliary Cholangitis (Pbc) Clinical Trial
Posted Date: Oct 7, 2021
- Investigator: Kenneth Sherman
- Specialties: Gastroenterology, Liver Disease
- Type of Study: Drug
TRANSFORM: A 52-week, Randomized, Placebo-controlled, Double-blind, Adaptive Phase 2b/3 Trial of Setanaxib with a 52-week Extension Phase in Patients with Primary Biliary Cholangitis (PBC) and Elevated Liver Stiffness
Criteria:
Eligible Patients Must Have A Diagnosis Of Pbc.
Keywords:
Pbc, Cirrhosis, Fibrosis
For More Information:
Liz Stambrook
513-584-2363
stambre@ucmail.uc.edu